AR089011A1 - 2h-indazoles como antagonistas del receptor ep₂ - Google Patents

2h-indazoles como antagonistas del receptor ep₂

Info

Publication number
AR089011A1
AR089011A1 ARP120104465A ARP120104465A AR089011A1 AR 089011 A1 AR089011 A1 AR 089011A1 AR P120104465 A ARP120104465 A AR P120104465A AR P120104465 A ARP120104465 A AR P120104465A AR 089011 A1 AR089011 A1 AR 089011A1
Authority
AR
Argentina
Prior art keywords
alkyl
residue
cycloalkyl
membered
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
ARP120104465A
Other languages
English (en)
Inventor
Dra Rotgeri Andrea
Dr Bruer Nico
Dr Ter Laak Antonius
Dr Buchmann Bernd
Dr Lindenthal Bernhard
Dra Rhn Ulrike
Dra Mengel Anne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Intellectual Property GmbH
Original Assignee
Bayer Intellectual Property GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47278803&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR089011(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Intellectual Property GmbH filed Critical Bayer Intellectual Property GmbH
Publication of AR089011A1 publication Critical patent/AR089011A1/es
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)

Abstract

La presente se refiere a 2H-indazoles de la fórmula general (1), métodos para su preparación y su uso para la producción de agentes farmacéuticos para el tratamiento de enfermedades e indicaciones que están ligadas con el receptor de EP₂, enfermedades relativas a la biología reproductiva femenina (menorragia, dismenorrea, endometriosis, procesos neurodegenerativos, etc.). Reivindicación 1: Compuestos de la fórmula general (1) en donde R¹: significa H, alquilo C₁₋₂ o alquil C₁₋₂-oxi; R²: es H o metilo; siempre que uno de los dos residuos R¹ o R² sea H; X: es -(CH₂)ₗ-, -(CH₂)ₖ-O-, -CH₂-S-, CH₂-S(O)₂-, -CH(CH₃)-, -CH(CH₃)-O- o -C(CH₃)₂-O-; k: es 1 ó 2; I: es 0, 1 ó 2; R⁴: H, alquilo C₁₋₄, cicloalquilo C₃₋₄ o CH₂-cicloalquilo C₃₋₄; y el caso de que X: -CH₂- o -CH(CH₃)- R⁴: significa adicionalmente un residuo de heterociclilo de 4 - 6 miembros; el caso de que X: -(CH₂)ₗ- o -CH(CH₃)- R⁴: significa adicionalmente CN; o X junto con R⁴ forman un residuo de heterociclilo de 4 - 6 miembros por medio de una ligación de carbono de anillo; m: es 1 ó 2; n: es 1 ó 2; Ar: es un residuo de arilo de 6 - 10 miembros o residuo de hetarilo de 5 - 10 miembros, R³: es halógeno, CN, SF₅, alquilo C₁₋₄, cicloalquilo C₃₋₆, heterociclilo C₄₋₆, O-alquilo C₁₋₄, O-cicloalquilo C₃₋₆, O-heterociclilo C₄₋₆, S-alquilo C₁₋₄, S(O)₂-alquilo C₁₋₄, Ar, O-Ar, C(CH₃)₂-CN o C(CH₃)₂-OH; y Ar: un residuo de arilo de 6 miembros o residuo de heteroarilo de 5 - 6 miembros opcionalmente mono- o disustituido; en donde los sustituyentes están seleccionados de F, Cl, CN, alquilo C₁₋₄, O-alquilo C₁₋₄, C₍CH₃)₂-CN, C(CH₃)₂-OH y C(O)NH₂; y sus isómeros, diastereómeros, enantiómeros y sales o clatratos de ciclodextrina.
ARP120104465A 2011-11-28 2012-11-28 2h-indazoles como antagonistas del receptor ep₂ Pending AR089011A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102011087170 2011-11-28
DE102012206715 2012-04-24

Publications (1)

Publication Number Publication Date
AR089011A1 true AR089011A1 (es) 2014-07-23

Family

ID=47278803

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120104465A Pending AR089011A1 (es) 2011-11-28 2012-11-28 2h-indazoles como antagonistas del receptor ep₂

Country Status (25)

Country Link
US (1) US9062041B2 (es)
EP (1) EP2785707B1 (es)
JP (1) JP6192654B2 (es)
KR (1) KR20140103984A (es)
CN (1) CN104144922B (es)
AR (1) AR089011A1 (es)
AU (1) AU2012344015A1 (es)
BR (1) BR112014012459A2 (es)
CA (1) CA2856769A1 (es)
CL (1) CL2014001392A1 (es)
CO (1) CO6970595A2 (es)
CR (1) CR20140257A (es)
DO (1) DOP2014000114A (es)
EA (1) EA201400623A1 (es)
EC (1) ECSP14002542A (es)
ES (1) ES2665510T3 (es)
HK (1) HK1203938A1 (es)
IL (1) IL232503A (es)
IN (1) IN2014CN03854A (es)
MX (1) MX2014006433A (es)
PE (1) PE20141579A1 (es)
PH (1) PH12014501195A1 (es)
SG (1) SG11201402269RA (es)
TW (1) TW201326154A (es)
WO (1) WO2013079425A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR087814A1 (es) 2011-09-16 2014-04-16 Fovea Pharmaceuticals Derivados de anilina, su preparacion y su aplicacion terapeutica
TW201326154A (zh) 2011-11-28 2013-07-01 拜耳知識產權公司 作為ｅｐ２受體拮抗劑之新穎２ｈ－吲唑
BR112015029214A2 (pt) * 2013-05-23 2017-07-25 Bayer Pharma AG composição farmacêutica, seu uso e regime de aplicação dessa composição farmacêutica para contracepção conforme a necessidade
WO2014187793A1 (de) * 2013-05-23 2014-11-27 Bayer Pharma Aktiengesellschaft Verwendung einer pharmazeutischen zusammensetzung zur notfallkontrazeption
CN106535884A (zh) 2014-06-06 2017-03-22 弗雷克萨斯生物科学公司 免疫调节剂
UY36391A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen
EP3215141A4 (en) 2014-11-05 2018-06-06 Flexus Biosciences, Inc. Immunoregulatory agents
UY36390A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
UY38455A (es) 2018-11-08 2020-05-29 Glaxosmithkline Ip Dev Ltd Nuevos compuestos inhibidores de la prostaglandina d sintasa hematopoyética (h-pgds)
JPWO2022138792A1 (es) * 2020-12-24 2022-06-30

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL127441A (en) 1996-07-18 2003-02-12 Merck Frosst Canada Inc Substituted pyridines, pharmaceutical compositions comprising them and their use in the preparation of anti-inflammatory medicaments or as selective cyclooxygenase-2 inhibitors
US5861419A (en) 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
HN2001000224A (es) * 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
JP4529119B2 (ja) 2001-08-09 2010-08-25 小野薬品工業株式会社 カルボン酸誘導体化合物およびその化合物を有効成分として含有する薬剤
EP1467738A1 (en) 2001-10-08 2004-10-20 Medical Research Council Use of prostaglandin e synthase inhibitors, or ep2 or ep4 receptor antagonists, in the treatment of a pathological condition of the uterus
WO2003035064A1 (en) 2001-10-23 2003-05-01 Applied Research Systems Ars Holding N.V. Pyrazolidinone compounds as ligands of the prostaglandin ep2 and/or ep4 receptors
JP2005511562A (ja) 2001-10-31 2005-04-28 メディカル リサーチ カウンシル 月経困難症及び月経過多の治療のためのプロスタグランジンレセプターｅｐ２及び／又はｅｐ４のアンタゴニスト
EP1458679B1 (en) 2001-12-20 2010-01-20 Merck Serono SA Pyrrolidine derivatives as prostaglandin modulators
HUP0500012A2 (hu) 2002-01-31 2005-04-28 Pfizer Products Inc. A (3-{[4-terc-butil-benzil)-(piridin-3-szulfonil)-amino]-metil}-fenoxi)-ecetsav metabolitjai és ezeket hatóanyagként tartalmazó gyógyszerkészítmények
JP4547912B2 (ja) 2002-03-05 2010-09-22 小野薬品工業株式会社 ８−アザプロスタグランジン誘導体化合物およびその化合物を有効成分として含有する薬剤
AU2003272962A1 (en) 2002-10-10 2004-05-04 Shuh Narumiya Remedies for allergic diseases
WO2006104406A1 (en) 2005-03-31 2006-10-05 Auckland Uniservices Limited Tricyclic 1,2,4-triazine oxides and compositions therefrom for therapeutic use in cancer treatments
ATE388936T1 (de) 2005-11-21 2008-03-15 Bayer Schering Pharma Ag 9-chloro-15-deoxyprostaglandinderivate, verfahren zu ihrer herstellung und deren verwendung als medikamente
DE102005062741A1 (de) 2005-12-22 2007-06-28 Bayer Schering Pharma Ag Fluorene und Carbazole als Liganden des EP2 Rezeptors
KR20090005296A (ko) 2006-02-10 2009-01-13 서미트 코포레이션 피엘씨 뒤시엔느 근이영양증의 치료
EP1884906A1 (de) 2006-07-31 2008-02-06 Siemens Building Technologies Fire & Security Products GmbH & Co. oHG Levelsynchronisation bei Funk-Kommunikationsnetzwerken
EP1903037A1 (de) 2006-09-07 2008-03-26 Bayer Schering Pharma Aktiengesellschaft 1-(Het)aryl-3-[hetaryl-piperidin-4-yl]-thioharnstoffe als Modulatoren des EP2-Rezeptors
EP1903038A1 (de) 2006-09-07 2008-03-26 Bayer Schering Pharma Aktiengesellschaft N-(1-Hetaryl-piperidin-4-yl)-(het)arylamide als EP2-Rezeptor Modulatoren
EP1900731A1 (de) 2006-09-07 2008-03-19 Bayer Schering Pharma Aktiengesellschaft N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren
AU2007329480A1 (en) 2006-12-05 2008-06-12 National Chio Tung University Indazole compounds
CN101679235A (zh) 2007-05-10 2010-03-24 辉瑞有限公司 氮杂环丁烷衍生物和它们作为前列腺素e2拮抗剂的用途
EP2003118A1 (de) 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Zimtsäurederivate als Modulatoren des EP2-Rezeptors
EP2003119A1 (de) 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Substituierte Acetamide als Modulatoren des EP2-Rezeptors
EP2002834A1 (de) 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Aryl/Hetarylamide als Modulatoren des EP2-Rezeptors
EP2014662A1 (de) 2007-07-12 2009-01-14 Bayer Schering Pharma Aktiengesellschaft Indolylalkylthienopyrimidylamine als Modulatoren des EP2-Rezeptors
EP2014663A1 (de) 2007-07-12 2009-01-14 Bayer Schering Pharma AG Thienopyrimidylamine als Modulatoren des EP2-Rezeptors
CA2705368A1 (en) * 2007-11-15 2009-05-22 Pfizer Limited Azetidines as ep2 antagonists
PT2565191E (pt) * 2008-05-14 2014-12-04 Astellas Pharma Inc Derivados do ácido 4-(indol-7- ilcarbonilaminometil)ciclo-hexanocarboxílico como antagonistas de receptores ep4, úteis no tratamento de insuficiência renal crónica ou de nefropatia diabética
WO2010008777A2 (en) 2008-06-23 2010-01-21 Ligand Pharmaceuticals Inc. Fused azabicyclic pyridines
EP2364296A1 (en) 2008-11-10 2011-09-14 Pfizer Limited Pyrrolidines
WO2010080357A1 (en) * 2008-12-18 2010-07-15 Boehringer Ingelheim International Gmbh Serotonin 5-ht2b receptor inhibitors
TW201107315A (en) * 2009-07-27 2011-03-01 Kissei Pharmaceutical Indole derivatives, or the pharmaceutically acceptable salts
DE102009049662A1 (de) 2009-10-13 2011-04-14 Bayer Schering Pharma Aktiengesellschaft 2,5-Disubstituierte 2H-Indazole als EP2-Rezeptor-Antagonisten
TW201326154A (zh) 2011-11-28 2013-07-01 拜耳知識產權公司 作為ｅｐ２受體拮抗劑之新穎２ｈ－吲唑

Also Published As

Publication number Publication date
MX2014006433A (es) 2014-07-11
KR20140103984A (ko) 2014-08-27
DOP2014000114A (es) 2014-07-15
US20140336172A1 (en) 2014-11-13
PH12014501195A1 (en) 2014-09-01
IN2014CN03854A (es) 2015-09-04
EA201400623A1 (ru) 2014-11-28
TW201326154A (zh) 2013-07-01
CO6970595A2 (es) 2014-06-13
JP6192654B2 (ja) 2017-09-06
SG11201402269RA (en) 2014-09-26
CA2856769A1 (en) 2013-06-06
EP2785707A1 (en) 2014-10-08
AU2012344015A1 (en) 2014-05-29
HK1203938A1 (en) 2015-11-06
EP2785707B1 (en) 2018-01-24
CR20140257A (es) 2014-07-15
CL2014001392A1 (es) 2014-10-03
IL232503A0 (en) 2014-07-01
US9062041B2 (en) 2015-06-23
NZ624722A (en) 2016-08-26
WO2013079425A1 (en) 2013-06-06
ECSP14002542A (es) 2015-12-31
ES2665510T3 (es) 2018-04-26
IL232503A (en) 2015-08-31
CN104144922A (zh) 2014-11-12
CN104144922B (zh) 2016-08-31
BR112014012459A2 (pt) 2017-06-06
JP2014533713A (ja) 2014-12-15
PE20141579A1 (es) 2014-11-15

Similar Documents

Publication Publication Date Title
AR089011A1 (es) 2h-indazoles como antagonistas del receptor ep₂
CY1120480T1 (el) Ενωσεις πυραζολοπυριμιδινης
DOP2016000299A (es) Derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y su uso como inhibidores ido1
CY1119422T1 (el) Παραγωγα μπετουλινης
EA201790407A1 (ru) Зонды для визуализации белка хантингтина
CY1124537T1 (el) Παραγωγο πυριδονης που εχει τετραϋδροπυρανυλ μεθυλ ομαδα
EA201992183A2 (ru) Синтез полициклических карбамоилпиридоновых соединений
CR20160098A (es) Polimorfo de los inhibidores de la syk
CR20140548A (es) Derivados de aril-sultamo como moduladores de rorc
CO7170131A2 (es) Compuestos de heterociclilo
CR20130051A (es) Promotores de apoptosis de n-acilsulfonamidas
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
CR20150061A (es) Compuesto de pirazolopirimidinas
EA201591815A1 (ru) Бицикло [2.2.2] кислоты - модуляторы gpr120
EA201790400A1 (ru) Зонды для визуализации белка хантингтина
CY1125355T1 (el) Πεντακυκλικη ενωση
CL2017001130A1 (es) Síntesis de copanlisib y su sal diclorhidrato
GT201400167A (es) Nuevos derivados de bencil sulfonamida utiles como inhibidores de mogat-2
UY36110A (es) Inhibidores de quinasa relacionados con tropomiosina
NI201200195A (es) Procedimiento de preparación de la sal de l - arginina de perindoprilo
CU20150006A7 (es) Derivados de (piperidin-4-il)piperazina-1-carboxamida/carboxilato útiles como antagonistas del receptor -h3
DOP2014000177A (es) Nuevos derivados de morofolinilo útiles como inhibidores de mogat-2
CL2017002498A1 (es) Piridopirimidinonas y su uso como modulares del receptor nmda
CY1122334T1 (el) Νεες κρυσταλλικες mopφeς του αλατος μονονατριου της φορμασουλφουρονης
AR097794A1 (es) Moduladores octahidro-ciclopenta[c]pirrol negativos de nr2b

Legal Events

Date Code Title Description
FB Suspension of granting procedure